Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma (NCT05874414)
Phase 1b/2a Study of GNS561 in Combination With Trametinib in Advanced KRAS Mutated Cholangiocarcinoma
🩺 Plain-English Summary (8th-Grade Level)
This is an open-label, multicenter Phase 1b/2a study to evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of GNS561 in combination with trametinib in Advanced KRAS Mutated Cholangiocarcinoma after failure of standard-of-care first line therapy
Who can join: Review the eligibility criteria below.
Location: USC Norris Comprehensive Cancer Center — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (11 Sites)
- USC Norris Comprehensive Cancer Center — Los Angeles, California
- LACN Aneheim Flagship Office — Los Angeles, California
- Orlando Health — Orlando, Florida
- Moffitt Cancer Center — Tampa, Florida
- University Of Chicago Medical Center — Chicago, Illinois
- Roswell Park Cancer Institute — Buffalo, New York
- Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania
- University of Texas, MD Anderson Cancer Center — Houston, Texas
- University of Virginia Comprehensive Cancer Center — Charlottesville, Virginia
- Froedtert Hospital and the Medical College of Wisconsin — Milwaukee, Wisconsin
- Pan American Center for Oncology Trials, LLC — Rio Piedras, Puerto Rico
📞 Contact the Study Coordinator
Phone: +33320164092
Email: contact@genfit.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cholangiocarcinoma
- Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations — Phoenix, Arizona
- An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma — Yerevan,
- Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma — Santa Monica, California
- [18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed Cholangiocarcinoma — Seattle, Washington
- Cell-Surface Plectin in the Diagnosis of Cholangiocarcinoma from ERCP-directed Biliary Samples — Charlottesville, Virginia
- Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid — St Louis, Missouri
Explore by condition: All Cholangiocarcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.